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Phase I P450 cytochromes and phase II glutathione-S-transferases
are supergene families involved with carcinogen metabolism.
Polymorphic variants at the GSTM1, GSTT1 and CYP1A1 loci
have been implicated in cancer risk for a number of cancers
including lung, bladder, gastrointestinal tract, skin, endometrium
and breast cancer (Xu et al, 1996; Rebbeck, 1997). As smoking is
a risk factor for pancreatic cancer, and highly penetrant genes have
a minor role in pancreatic aetiology (Flanders and Foulkes, 1996),
it is possible that a substantial population attributable risk could be
contributed by these genes. The present study was therefore under-
taken to examine GSTM1, GSTT1 and CYP1A1 polymorphisms as
potential molecular markers of pancreatic cancer susceptibility.
MATERIALS AND METHODS
Study population
Patients with newly diagnosed pancreatic cancer were enrolled
from the inpatient units, and outpatient cancer clinics of nine
tertiary care hospitals in Toronto and Montreal from July 1996 to
October 1998. Eligible adult patients received a histologically
confirmed diagnosis of pancreatic adenocarcinoma. A total of 161
cases were enrolled of 204 eligible cases (79% participation rate),
with patient refusal and terminal care being major reasons for non-
participation. Nine enrolled cases had significant missing geno-
type or interview information, two withdrew participation, and in
one case had already another sibling enrolled. So, 149 cases were
analysed.
For each patient, a spouse or unrelated family member (when
there was no spouse) from the same generation as the case (e.g.
brother-in-law) was selected as a control (n = 103). For those with
no family member control available (n = 43), an age-, gender- and
ethnically-matched population control was chosen. The population
controls were identified from a group of individuals recruited by
telephone from random-digit dialling techniques. Three cases
were multi-ethnic and no appropriate controls were found.
For each case and control, a questionnaire was administered
either in person or by telephone. Subjects were asked about their
age, smoking history, drinking history and past medical history.
Self-reported ethnicity was utilized through assessment of grand-
parents’ heritage and place of birth. Interviews were standardized
using scripted texts and standardized prompts. All subjects
provided a blood specimen. The protocol was approved by the
institutional review board of each hospital or university, and
informed consent was obtained from all participants.
Laboratory analysis
Polymerase chain reaction (PCR) amplifications were performed
from genomic DNA extracted from blood for all patients and
controls using standard methods. Genotyping of GSTM1 and
GSTT1 were performed by published methods (Zhong et al, 1993;
Pemble et al, 1994). In both cases, presence of an internal control
product concurrent with the absence of a GSTM1- or GSTT1-
specific product was indicative of homozygosity for the null allele.
The  CYP1A1 genotype was determined by PCR using allele-
specific primers of the isoleucine-valine polymorphism in residue
462 in exon 7 according to a modification of the method previ-
ously described (Rebbeck et al, 1994). Because the Msp polymor-
phism of CYP1A1 is tightly linked with the Ile-Val substitution,
and is rare (approximately 1%) in non-Japanese cohorts, only the
Ile-Val substitution was evaluated (Hirvonen, 1995). All PCR
assays were done without knowledge of case or control status.
Statistical analysis
Methods
Conditional logistic regression, excluding ethnically unmatched
cases, was used to estimate the initial odds ratios. However,
Polymorphisms in GSTM1, GSTT1 and CYP1A1 and risk
of pancreatic adenocarcinoma
G Liu1, P Ghadirian2, D Vesprini1, N Hamel3, A-J Paradis2, G Lal4, S Gallinger4, SA Narod1 and WD Foulkes3
1Centre for Research in Women’s Health, Women’s College Hospital, University of Toronto, Toronto, Canada, M5G 1N8; 2Centre de Recherche, Pavillon Hotel
Dieu, CHUM, Montreal, Quebec, Canada, H2W 1T8; 3Montreal General Hospital Research Institute, Department of Medicine, McGill University, Montreal
Quebec, Canada, H3G 1A4; 4Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, University of Toronto, Toronto, Canada, 
M5G 1X5
Summary A prospective study of 149 unselected incident cases of pancreatic adenocarcinoma and 146 ethnically-matched controls found 
no associations between GSTM1 (adjusted odds ratio (AOR) 1.14), GSTT1 (AOR: 1.19) and CYP1A1 (AOR: 1.08) polymorphisms and
pancreatic cancer susceptibility. Smoking and drinking status did not affect results. These polymorphisms do not appear to be important gene
modifiers in pancreatic cancer. © 2000 Cancer Research Campaign
Keywords: pancreatic cancer; genetic susceptibility; cytochrome P450; glutathione S-transferase
1646
Received 22 July 1999
Revised 22 November 1999
Accepted 24 January 2000
Correspondence to: G Liu, Dana 1056, Dana-Farber Cancer Institute, 44
Binney Street, Boston, MA 02115, USA
British Journal of Cancer (2000) 82(10), 1646–1649
© 2000 Cancer Research Campaign
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results to unmatched logistic regression, the final analysis
performed was an unmatched logistic regression, using the SAS
program, and included all cases and controls. The following
factors were controlled for in the analysis: age (within 5 years),
gender, centre attended (Toronto vs Montreal), ethnicity, smoking
and drinking status. Interactions among the different polymor-
phisms and smoking were performed as secondary analyses.
Power
At a two-sided a (alpha) of 0.05, with 150 cases and 150 controls,
where the expected controls had a prevalence of the null genotype
of 50% for GSTM1, 20% for GSTT1 and 20% for the variant
CYP1A1, we have an 80% power to detect an odds ratio for
pancreatic cancer risk between genotypes of ³ 1.7 (GSTM1); ³ 2.0
(GSTT1 and CYP1A1).
RESULTS
The study population is described in Table 1. The ratio of males
and females in the cases is similar to that observed in the Canadian
population with pancreatic cancer. There were no differences in
ethnicity mix, gender, or age between cases and controls. There
were trends for more smokers (P = 0.06) and drinkers (P = 0.07) to
have pancreatic cancer. Pancreatitis and diabetes were more
frequent in the cases, but this effect disappeared when only those
conditions which appeared more than 3 years before the time 
of diagnosis were considered (P > 0.20 for both conditions),
suggesting that these medical conditions were actually the first
manifestations of pancreatic cancer.
Genotype data are provided in Table 2. There were no differ-
ences (P > 0.60 for all genotypes) between cases and controls in
GSTM1, GSTT1 and CYP1A1 genotype distribution. The preva-
lence of the control null or variant genotypes is similar to those
found in other Western population studies (Hirvonen, 1995;
Rebbeck, 1997). No differences were found when the data were
stratified by ethnicity.
The overall adjusted odds ratio for pancreatic cancer with the
GSTM1 null genotype was 1.14 (95% confidence interval (CI)
0.71–1.81), GSTT1 null genotype 1.19 (95% CI 0.66–2.16), and
CYP1A1 variant, 1.08 (95% CI 0.51–2.14), adjusting for
drinking, smoking and ethnicity. The unadjusted odds ratios
(GSTM1 null 1.13; GSTT1 null 1.19; CYP1A1 variant 1.08) were
similar to the adjusted odds ratios. In the logistic regression
analyses, smoking and drinking status, ethnicity, and genotype
status were not found to influence the development of pancreatic
cancer. The P-values for all models examined were greater than
0.20. Subset analyses did not show any interactions amongst the
different polymorphisms and the development of pancreatic
cancer.
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Table 1 Characteristics of the study population
Cases Controls
n (%) n (%) P-valuea
Median age, years (range) 66 (24–83) 64 (29–77) n.a.
Gender
Male 79 (53) 76 (52) n.a.
Female 70 (47) 70 (48)
Ethnicityb
French/French Canadian 63 (42) 63 (43) n.a.
British/Irish 39 (26) 39 (27)
Other European 23 (15) 23 (16)
Ashkenazi Jewish 13 (8) 13 (8)
Asian/Arab 8 (5) 8 (5)
Other/multi-ethnic 3 (2) 0 (0)
Smoking statusc
Never 84 (56) 96 (66) 0.06
Light 33 (22) 30 (26)
Heavy 32 (21) 20 (15)
Drinking statusd
Never 67 (45) 85 (58) 0.07
Light 45 (30) 32 (22)
Heavy 37 (25) 29 (20)
Pancreatitis
Ever 9 (6) 0 (0) 0.004
> 3 years before diagnosis 3 (2) 0 (0) 0.25
Diabetes mellitus
Ever 13 (9) 3 (2) 0.02
> 3 years before diagnosis 5 (3) 3 (2) 0.73
an.a. = non-applicable; c2 trend test for smoking and drinking; c2 tests or Fisher’s exact tests for all other categories.
bEthnicity was defined as having at least three grandparents in the same ethnicity category. All others were classified as
multi-ethnic. cNon-smokers had fewer than 100 cigarettes in their lifetime; light smokers had 30 lifetime pack-years (product
of number of packs per day ´ number of years smoking) or fewer; and heavy smokers, more than 30 pack-years. Twenty-five
cigarettes constituted one pack. dLight drinkers have 50 or fewer drink-years. One drink was equivalent to one bottle of beer,
one glass of wine, or one shot of hard liquor.1648 G Liu et al
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DISCUSSION
Although pancreatic cancer is an important cause of cancer death,
genetic factors involved with the aetiology of the disease have not
been extensively studied. Previous smaller studies found no asso-
ciations with CYP1A1 polymorphisms or GSTM1 null genotypes
(Lee et al, 1997; Bartsch et al, 1998). Our study confirmed a lack
of association between pancreatic adenocarcinoma and GSTT1,
GSTM1 null-genotypes, or the CYP1A1 variant. Further, neither
smoking status nor alcohol use influenced our results. The strength
of the current study is the use of ethnically matched controls.
Ethnicity has been shown to greatly affect genotype status
(Rebbeck, 1997). The mix of ethnicities in this study allowed for a
subset analysis, which showed non-significant risk differences in
Caucasian, Jewish or non-Caucasian patients.
The use of spousal controls aimed to decrease the environmental
and ethnic differences between cases and controls (Foulkes et al,
1996), and we were successful in obtaining more than half of our
controls as spouses. It is this overmatching which possibly led to a
non-significant trend for smokers to develop pancreatic cancer in
this population (P = 0.06, Table 2).
This study had several limitations. Small and modest differ-
ences in risk (relative risks less than 1.7–2.0) would have been
missed. The study did not evaluate GSTM1 subtypes A and B,
although there has never been a clear functional difference
between these subtypes (Rebbeck, 1997). In vitro studies suggest
that the Ile-Val CYP1A1 polymorphism has no functional conse-
quences (Zhang et al, 1996; Persson et al, 1997) and the functional
significance of the MspI allele is still unknown. This study did not
evaluate the interaction of genotypes and dietary factors. Different
dietary factors have been associated with pancreatic cancer, but
none consistently (Howe and Burtch, 1996). The potential interac-
tions between several dietary factors and genotypes would be
enormous, requiring thousands of pancreatic cancer patients.
In conclusion, we found that GSTM1, GSTT1 homozygous
null genotypes and the CYP1A1 (Ile-Val) genotype are not over-
represented in pancreatic cancer patients, and interactions
between tobacco and alcohol and polymorphic variation are not
observed. There are a number of reasons for a lack of association
between these polymorphisms, smoking, and the development of
pancreatic cancer. First, GSTM1, GSTT1 and CYP1A1 may not be
among the enzymes involved in the metabolism of the carcino-
gens responsible for carcinogenesis. Repair genes, such as O6-
methyguanine-DNA methyltransferase, might be the primary
genetic modifiers of pancreatic cancer risk. Secondly, these poly-
morphisms are themselves inadequate to modify a person’s risk,
and require other genetic or environmental modifiers not yet
identified. Future studies will need to address these areas of
research.
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Table 2 Genotype characteristics of study population
Cases Controls
Null/variant Present/standard Null/variant Present/standard
n (%) n (%) n (%) n (%)
GST-M1 81 (54) 68 (45) 75 (51) 71 (49)
subgroups:
French/French Canadian 36 27 37 26
British/Irish 21 18 17 22
Other European 13 10 9 14
Ashkenazi Jewish 6 7 7 6
Asian/Arab 3 5 5 3
Other/multi-ethnic 2 1 0 0
GST-T1 30 (20) 119 (80) 26 (18) 119* (82)
subgroups:
French/French Canadian 6 57 11 32
British/Irish 9 30 7 32
Other European 8 15 5 18
Ashkenazi Jewish 2 11 2 10
Asian/Arab 4 4 1 7
Other/multi-ethnic 1 2 0 0
CYP1A1 20 (13) 129 (87) 19 (13) 127 (87)
subgroups:
French/French Canadian 7 56 9 54
British/Irish 4 35 4 35
Other European 5 18 4 19
Ashkenazi Jewish 0 13 0 13
Asian/Arab 3 5 2 6
Other/multi-ethnic 1 2 0 0
aOne control did not have GST-T1 genotype data.GST-M1, GST-T1, CYP1A1 loci in pancreatic cancer 1649
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